<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p37" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_37{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_37{left:341px;bottom:30px;}
#t3_37{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_37{left:377px;bottom:30px;}
#t5_37{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_37{left:540px;bottom:30px;}
#t7_37{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_37{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_37{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_37{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_37{left:285px;bottom:827px;letter-spacing:-0.26px;}
#tc_37{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_37{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_37{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_37{left:1106px;bottom:28px;letter-spacing:0.34px;}
#tg_37{left:36px;bottom:235px;}
#th_37{left:46px;bottom:229px;letter-spacing:0.08px;word-spacing:-0.01px;}
#ti_37{left:377px;bottom:229px;letter-spacing:0.12px;}
#tj_37{left:407px;bottom:229px;letter-spacing:0.13px;}
#tk_37{left:481px;bottom:229px;}
#tl_37{left:36px;bottom:218px;}
#tm_37{left:46px;bottom:212px;letter-spacing:0.12px;}
#tn_37{left:36px;bottom:201px;}
#to_37{left:46px;bottom:195px;letter-spacing:0.1px;word-spacing:-0.02px;}
#tp_37{left:45px;bottom:179px;letter-spacing:0.13px;}
#tq_37{left:36px;bottom:168px;}
#tr_37{left:46px;bottom:162px;letter-spacing:0.11px;word-spacing:-0.02px;}
#ts_37{left:45px;bottom:145px;letter-spacing:0.12px;}
#tt_37{left:36px;bottom:134px;}
#tu_37{left:46px;bottom:128px;letter-spacing:0.12px;word-spacing:0.01px;}
#tv_37{left:36px;bottom:117px;}
#tw_37{left:46px;bottom:111px;letter-spacing:0.12px;word-spacing:-0.03px;}
#tx_37{left:556px;bottom:111px;}
#ty_37{left:438px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.22px;}
#tz_37{left:765px;bottom:786px;}
#t10_37{left:36px;bottom:748px;letter-spacing:-0.1px;}
#t11_37{left:36px;bottom:729px;letter-spacing:-0.09px;word-spacing:-0.05px;}
#t12_37{left:36px;bottom:711px;letter-spacing:-0.1px;}
#t13_37{left:41px;bottom:693px;}
#t14_37{left:58px;bottom:693px;letter-spacing:-0.09px;}
#t15_37{left:58px;bottom:674px;letter-spacing:-0.09px;}
#t16_37{left:63px;bottom:656px;}
#t17_37{left:76px;bottom:656px;letter-spacing:-0.09px;}
#t18_37{left:614px;bottom:663px;letter-spacing:-0.12px;}
#t19_37{left:63px;bottom:638px;}
#t1a_37{left:76px;bottom:638px;letter-spacing:-0.09px;}
#t1b_37{left:566px;bottom:645px;}
#t1c_37{left:41px;bottom:619px;}
#t1d_37{left:58px;bottom:619px;letter-spacing:-0.09px;}
#t1e_37{left:63px;bottom:601px;}
#t1f_37{left:76px;bottom:601px;letter-spacing:-0.09px;}
#t1g_37{left:547px;bottom:608px;}
#t1h_37{left:36px;bottom:564px;letter-spacing:0.34px;word-spacing:-0.18px;}
#t1i_37{left:378px;bottom:572px;}
#t1j_37{left:36px;bottom:546px;letter-spacing:-0.09px;}
#t1k_37{left:36px;bottom:528px;letter-spacing:-0.1px;}
#t1l_37{left:41px;bottom:509px;}
#t1m_37{left:58px;bottom:509px;letter-spacing:-0.11px;word-spacing:0.02px;}
#t1n_37{left:753px;bottom:517px;}
#t1o_37{left:41px;bottom:491px;}
#t1p_37{left:58px;bottom:491px;letter-spacing:-0.09px;}
#t1q_37{left:733px;bottom:498px;}
#t1r_37{left:36px;bottom:436px;letter-spacing:-0.1px;}
#t1s_37{left:619px;bottom:436px;letter-spacing:-0.1px;}
#t1t_37{left:677px;bottom:436px;letter-spacing:-0.09px;}
#t1u_37{left:36px;bottom:399px;letter-spacing:-0.1px;}
#t1v_37{left:36px;bottom:381px;letter-spacing:-0.11px;word-spacing:0.01px;}
#t1w_37{left:36px;bottom:363px;letter-spacing:-0.1px;}
#t1x_37{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_37{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_37{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_37{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_37{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_37{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_37{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_37{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_37{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_37{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_37{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sa_37{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_37{font-size:17px;font-family:Webdings_k6;color:#000;}
.sc_37{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sd_37{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.se_37{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sf_37{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts37" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg37Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg37" style="-webkit-user-select: none;"><object width="1210" height="935" data="37/37.svg" type="image/svg+xml" id="pdf37" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_37" class="t s0_37">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_37" class="t s1_37">® </span>
<span id="t3_37" class="t s0_37">(NCCN </span>
<span id="t4_37" class="t s1_37">® </span>
<span id="t5_37" class="t s0_37">), All rights reserved. NCCN Guidelines </span>
<span id="t6_37" class="t s1_37">® </span>
<span id="t7_37" class="t s0_37">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_37" class="t s2_37">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_37" class="t s2_37">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_37" class="t s3_37">NCCN Guidelines Version 4.2024 </span>
<span id="tb_37" class="t s3_37">Cancer of the Nasopharynx </span>
<span id="tc_37" class="t s4_37">NCCN Guidelines Index </span>
<span id="td_37" class="t s4_37">Table of Contents </span>
<span id="te_37" class="t s4_37">Discussion </span>
<span id="tf_37" class="t s5_37">NASO-A </span>
<span id="tg_37" class="t s6_37">1 </span>
<span id="th_37" class="t s7_37">See Principles of Radiation Techniques (RAD-A) </span><span id="ti_37" class="t s8_37">and </span><span id="tj_37" class="t s7_37">Discussion</span><span id="tk_37" class="t s8_37">. </span>
<span id="tl_37" class="t s6_37">2 </span>
<span id="tm_37" class="t s8_37">Care should be taken to avoid critical neural structures; therefore, 1.8 Gy/fraction can be considered. </span>
<span id="tn_37" class="t s6_37">3 </span>
<span id="to_37" class="t s9_37">For doses &gt;70 Gy, some clinicians feel that the fractionation should be slightly modified (eg, &lt;2.0 Gy/fraction for at least some of the treatment) to minimize toxicity. An </span>
<span id="tp_37" class="t s8_37">additional 2–3 doses can be added depending on clinical circumstances. </span>
<span id="tq_37" class="t s6_37">4 </span>
<span id="tr_37" class="t s9_37">Lee NY, Zhang Q, Pfister DG, et al. Addition of bevacizumab to standard systemic therapy/RT for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a </span>
<span id="ts_37" class="t s8_37">phase 2 multi-institutional trial. Lancet Oncol 2012;13:172-180. </span>
<span id="tt_37" class="t s6_37">5 </span>
<span id="tu_37" class="t s8_37">Suggest 44–50 Gy in sequentially planned IMRT or 54–63 Gy with IMRT dose painting technique (dependent on dose per fraction). </span>
<span id="tv_37" class="t s6_37">6 </span>
<span id="tw_37" class="t s7_37">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)</span><span id="tx_37" class="t s8_37">. </span>
<span id="ty_37" class="t s5_37">PRINCIPLES OF RADIATION THERAPY </span>
<span id="tz_37" class="t sa_37">1 </span>
<span id="t10_37" class="t s5_37">DEFINITIVE: </span>
<span id="t11_37" class="t s5_37">RT Alone (for T1,N0 or patients who are not eligible to receive chemotherapy) </span>
<span id="t12_37" class="t s5_37">• PTV </span>
<span id="t13_37" class="t sb_37"></span><span id="t14_37" class="t sc_37" data-mappings='[[94,"fi"]]'>High risk: Primary tumor and involved lymph nodes [this includes possible local subclinical inﬁltration at the primary site and at the high- </span>
<span id="t15_37" class="t s5_37">risk level lymph node(s)] </span>
<span id="t16_37" class="t sd_37">◊ </span><span id="t17_37" class="t s5_37">70–70.2 Gy (1.8–2.0 Gy/fraction); daily Monday–Friday in 7–8 weeks </span>
<span id="t18_37" class="t sa_37">2,3 </span>
<span id="t19_37" class="t sd_37">◊ </span><span id="t1a_37" class="t s5_37">69.96 Gy (2.12 Gy/fraction) daily Monday–Friday in 6–7 weeks </span>
<span id="t1b_37" class="t sa_37">4 </span>
<span id="t1c_37" class="t sb_37"></span><span id="t1d_37" class="t s5_37">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t1e_37" class="t sd_37">◊ </span><span id="t1f_37" class="t s5_37">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t1g_37" class="t sa_37">5 </span>
<span id="t1h_37" class="t s5_37">CONCURRENT SYSTEMIC THERAPY/RT: </span>
<span id="t1i_37" class="t sa_37">6 </span>
<span id="t1j_37" class="t s5_37">(preferred for patients eligible for chemotherapy) </span>
<span id="t1k_37" class="t s5_37">• PTV </span>
<span id="t1l_37" class="t sb_37"></span><span id="t1m_37" class="t s5_37">High risk: Typically 70–70.2 Gy (1.8–2.0 Gy/fraction); daily Monday–Friday in 7–8 weeks </span>
<span id="t1n_37" class="t sa_37">2 </span>
<span id="t1o_37" class="t sb_37"></span><span id="t1p_37" class="t s5_37">Low to intermediate risk: 44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t1q_37" class="t sa_37">5 </span>
<span id="t1r_37" class="t s5_37">Hyperfractionation for locally advanced nasopharyngeal carcinoma: See </span><span id="t1s_37" class="t se_37">RAD-A </span><span id="t1t_37" class="t s5_37">for irradiation dosing schedule. </span>
<span id="t1u_37" class="t s5_37">IMRT is recommended for cancers of the nasopharynx to minimize dose to critical structures. Proton therapy can be considered when normal </span>
<span id="t1v_37" class="t s5_37">tissue constraints cannot be met by photon-based therapy, or when photon-based therapy causes compromise of standard radiation dosing </span>
<span id="t1w_37" class="t s5_37">to tumor or postoperative volumes. </span>
<span id="t1x_37" class="t sf_37">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
